Protalix BioTherapeutics, Inc. Appoints David Granot to Its Board of Directors
August 13, 2018 at 07:10 am EDT
Share
On August 13, 2018 Protalix BioTherapeutics, Inc. announced that the company’s Board of Directors has appointed Mr. David Granot to serve on the Company’s Board of Directors, effective on August 9, 2018. In addition to Mr. Granot’s appointment as an independent director, he was also appointed to serve on the Company’s Audit Committee. Mr. Granot currently serves on the Board of Directors of Ormat Technologies, Inc. He also serves on the board of directors of Bezeq Israeli Telecommunication Co. Ltd. since May 22, 2012, where he served as temporary Acting Chairman, July 2017 through May 2018.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.